Barbara A Phelps-Sandall, MD
Obstetrics/Gynecology · Redwood City
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 24
- 5 carriers
- Office
- 1
Offices
1 location · UCSF Health Medical Foundation · 40 clinicians in this group
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plans that list them
24 plans · 5 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Phelps-Sandall’s office at (650) 701-1882 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
24 of 24 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$31,075
Medicare paid this office $31,075 for 146 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 48 | $6,596 | $106 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 68 | $3,905 | $57 |
| Short return visit (20+ min) | 37 | $3,740 | $78 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 78 | $3,737 | $48 |
| Long return visit (40+ min) | 19 | $3,157 | $150 |
See all 6 services
| Return visit (30+ min) | 48 | $6,596 | $106 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 68 | $3,905 | $57 |
| Short return visit (20+ min) | 37 | $3,740 | $78 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 78 | $3,737 | $48 |
| Long return visit (40+ min) | 19 | $3,157 | $150 |
| Short return visit | 43 | $2,460 | $51 |
Who their Medicare patients are
146 Original Medicare patients in 2024. Average age 74 · Women 100% · Health risk score 0.76. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 55% · Diabetes 20% · Cancer 16% · Coronary heart disease 12% · Depression 12% · Chronic kidney disease 10%.
The office billed $129,606, Medicare allowed $40,427 and paid $31,075; for 385 services of 27 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 146 | 385 | 74 | 0.76 | $129,606 | $31,075 |
| 2023 | 117 | 292 | 74 | 0.72 | $108,999 | $23,062 |
| 2022 | 105 | 237 | 74 | 0.76 | $95,917 | $18,747 |
| 2021 | 103 | 246 | 73 | 0.64 | $100,085 | $21,603 |
| 2020 | 94 | 226 | 74 | 0.78 | $74,864 | $16,093 |
| 2019 | 113 | 262 | 73 | 0.80 | $35,734 | $20,163 |
| 2018 | 112 | 235 | 73 | 0.75 | $31,390 | $18,863 |
| 2017 | 118 | 273 | 73 | 0.91 | $41,379 | $20,074 |
| 2016 | 93 | 203 | 73 | 0.79 | $24,754 | $16,909 |
| 2015 | 101 | 261 | 73 | 0.80 | $29,428 | $19,385 |
| 2014 | 79 | 148 | 71 | 0.74 | $15,196 | $10,668 |
| 2013 | 73 | 159 | 74 | 0.82 | $27,213 | $13,673 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Return visit (30+ min) | 66 | $7,046 | $90 |
| Long return visit (40+ min) | 20 | $2,990 | $142 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 53 | $2,695 | $51 |
| Short return visit (20+ min) | 23 | $2,374 | $79 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 48 | $2,088 | $43 |
2022: 6 services
| Return visit (30+ min) | 39 | $4,237 | $101 |
| Long return visit (40+ min) | 16 | $2,491 | $156 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 46 | $2,375 | $52 |
| Short return visit (20+ min) | 23 | $1,788 | $69 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 37 | $1,657 | $45 |
| Short return visit | 13 | $881 | $44 |
2021: 5 services
| Return visit (30+ min) | 38 | $4,730 | $113 |
| Short return visit (20+ min) | 35 | $3,442 | $84 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 47 | $2,620 | $56 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 40 | $1,939 | $48 |
| Short return visit | 14 | $951 | $43 |
2020: 5 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 75 | $3,609 | $48 |
| Return visit (30+ min) | 27 | $3,210 | $97 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 42 | $2,290 | $55 |
| Short return visit (20+ min) | 17 | $1,523 | $66 |
| Short return visit | 12 | $503 | $39 |
2019: 3 services
| Return visit (30+ min) | 96 | $11,859 | $92 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 67 | $3,431 | $51 |
| Short return visit (20+ min) | 14 | $1,141 | $63 |
2018: 5 services
| Return visit (30+ min) | 75 | $9,747 | $99 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 46 | $2,576 | $56 |
| New patient visit (30+ min) | 14 | $1,441 | $103 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 22 | $1,016 | $46 |
| Short return visit (20+ min) | 13 | $984 | $70 |
2017: 4 services
| Return visit (30+ min) | 43 | $6,139 | $110 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 70 | $3,494 | $50 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 69 | $3,477 | $50 |
| Short return visit (20+ min) | 21 | $1,983 | $73 |
2016: 5 services
| Return visit (30+ min) | 44 | $5,491 | $93 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 30 | $3,845 | $128 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 35 | $1,774 | $51 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 29 | $1,224 | $42 |
| Short return visit (20+ min) | 15 | $968 | $61 |
2015: 5 services
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 68 | $3,489 | $51 |
| Return visit (30+ min) | 22 | $3,374 | $94 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 66 | $2,773 | $42 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 20 | $2,566 | $128 |
| Short return visit (20+ min) | 21 | $1,587 | $63 |
2014: 3 services
| Return visit (30+ min) | 33 | $3,962 | $92 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 34 | $1,671 | $49 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 34 | $1,451 | $43 |
2013: 3 services
| Return visit (30+ min) | 35 | $5,024 | $88 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 28 | $1,210 | $43 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 28 | $657 | $23 |
Drugs they prescribed that Part D paid
$15,822
Pharmacies billed $15,822 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
103 generic and 31 brand-name prescriptions · $15,822 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Estradiol | 16 | $2,089 | $70 |
Year by year
| 2024 | 134 | 43 | None | 23% | $15,822 |
| 2023 | 169 | 49 | None | None | $19,348 |
| 2022 | 178 | 51 | None | 25% | $25,925 |
| 2021 | 179 | 56 | None | 18% | $18,481 |
| 2020 | 152 | 55 | None | 22% | $24,311 |
| 2019 | 189 | 60 | None | None | $29,634 |
| 2018 | 167 | 46 | None | 29% | $26,844 |
| 2017 | 186 | 56 | None | 27% | $33,018 |
| 2016 | 169 | 51 | None | 30% | $25,798 |
| 2015 | 153 | 38 | None | 42% | $20,365 |
| 2014 | 121 | 33 | 0% (0) | 45% | $15,559 |
| 2013 | 105 | 30 | None | 58% | $11,674 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Estradiol | 48 | $4,659 | $97 |
| Clobetasol Propionate | 17 | $1,226 | $72 |
| Progesterone | 23 | $475 | $21 |
2022: 5 drugs
| Premarin | 18 | $7,985 | $444 |
| Estradiol | 49 | $3,757 | $77 |
| Clobetasol Propionate | 14 | $995 | $71 |
| Progesterone | 21 | $477 | $23 |
| Alendronate | 16 | $216 | $13 |
2021: 3 drugs
| Estradiol | 41 | $4,975 | $121 |
| Progesterone | 13 | $582 | $45 |
| Alendronate | 18 | $262 | $15 |
2020: 3 drugs
| Premarin | 20 | $7,993 | $400 |
| Estradiol | 37 | $5,901 | $159 |
| Alendronate | 26 | $370 | $14 |
2019: 5 drugs
| Premarin | 21 | $8,496 | $405 |
| Estradiol | 34 | $5,825 | $171 |
| Raloxifene | 15 | $5,062 | $337 |
| Tolterodine Tartrate Er | 11 | $2,755 | $250 |
| Alendronate | 25 | $428 | $17 |
2018: 4 drugs
| Premarin | 24 | $9,232 | $385 |
| Tolterodine Tartrate Er | 12 | $2,474 | $206 |
| Estradiol | 17 | $2,218 | $130 |
| Alendronate | 22 | $391 | $18 |
2017: 8 drugs
| Vagifem | 13 | $7,798 | $600 |
| Premarin | 13 | $5,094 | $392 |
| Raloxifene | 14 | $4,480 | $320 |
| Estrace | 11 | $3,133 | $285 |
| Tolterodine Tartrate Er | 13 | $2,725 | $210 |
| Estradiol | 17 | $1,659 | $98 |
| Alendronate | 15 | $111 | $7 |
| Triamcinolone Acetonide | 16 | $105 | $7 |
2016: 4 drugs
| Vagifem | 11 | $5,164 | $469 |
| Estrace | 19 | $4,948 | $260 |
| Prempro | 13 | $4,912 | $378 |
| Estradiol | 21 | $924 | $44 |
2015: 4 drugs
| Premarin | 22 | $4,688 | $213 |
| Prempro | 12 | $4,150 | $346 |
| Vagifem | 11 | $2,794 | $254 |
| Estradiol | 24 | $239 | $10 |
2014: 4 drugs
| Actonel | 21 | $4,327 | $206 |
| Premarin | 11 | $2,429 | $221 |
| Estrace | 12 | $1,996 | $166 |
| Estradiol | 12 | $133 | $11 |
2013: 3 drugs
| Prempro | 13 | $2,043 | $157 |
| Actonel | 11 | $2,034 | $185 |
| Combipatch | 12 | $1,013 | $84 |
Money from drug and device companies
$160 in 2025
| 2025 | 2 | 2 | None | $160 |
| 2024 | 1 | 4 | None | $61 |
| 2023 | 3 | 11 | None | $191 |
| 2022 | 4 | 8 | None | $366 |
| 2021 | 7 | 7 | None | $127 |
| 2020 | 2 | 2 | None | $133 |
| 2019 | 3 | 4 | None | $304 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| InSightec | Exablate | $143 | 1 payment
|
| CooperSurgical | Endosee | $17 | 1 payment
|
See all 2 published payments
| InSightec | Meals · 2025-08-26 | Exablate | $143 |
| CooperSurgical | Meals · 2025-01-29 | Endosee | $17 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $61
| Mayne Pharma Commercial | None | $61 | 4 payments
|
2023: $191
| Mayne Pharma Commercial | None | $139 | 8 payments
|
| Exact Sciences | Cologuard Collection Kit | $37 | 2 payments
|
| CooperSurgical | Paragard T 380a | $14 | 1 payment
|
2022: $366
| Hologic | Acessa Provu System | $140 | 1 payment
|
| Horizon Therapeutics plc | Tepezza | $117 | 1 payment
|
| Mayne Pharma | None | $74 | 4 payments
|
| Myovant Sciences | Myfembree | $35 | 2 payments
|
2021: $127
| Mylan Pharmaceuticals | Xulane | $24 | 1 payment
|
| AbbVie | Lo Loestrin Fe | $23 | 1 payment
|
| Exeltis USA | Slynd | $21 | 1 payment
|
| TherapeuticsMD | Annovera | $17 | 1 payment
|
| Myriad Genetic Laboratories | Myrisk | $15 | 1 payment
|
| Myovant Sciences | Myfembree | $14 | 1 payment
|
| Hologic | Acessa Provu System | $14 | 1 payment
|
2020: $133
| AbbVie | Orilissa | $121 | 1 payment
|
| Avion Pharmaceuticals | Balcoltra | $12 | 1 payment
|
2019: $304
| AbbVie | Orilissa | $227 | 2 payments
|
| Vermillion | Ova1 | $55 | 1 payment
|
| Allergan | Lo Loestrin Fe | $23 | 1 payment
|
Professional record
- NPI
- 1154363448
- Licence
- CA G 071692
- Trained
- University of California, Geffen School of Medicine, 1989
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 16201 Shannon Rd, Los Gatos, CA, 95032
- NPI first listed
- 2006-06-12
- NPI last updated
- 2016-02-10
This is when the NPI record was last certified, not a medical board exam.